226 related articles for article (PubMed ID: 16450142)
1. An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
Chan L; Hardwick NR; Guinn BA; Darling D; Gäken J; Galea-Lauri J; Ho AY; Mufti GJ; Farzaneh F
Cancer Immunol Immunother; 2006 Aug; 55(8):1017-24. PubMed ID: 16450142
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses.
Stripecke R; Cardoso AA; Pepper KA; Skelton DC; Yu XJ; Mascarenhas L; Weinberg KI; Nadler LM; Kohn DB
Blood; 2000 Aug; 96(4):1317-26. PubMed ID: 10942373
[TBL] [Abstract][Full Text] [Related]
3. Development of a whole cell vaccine for acute myeloid leukaemia.
Cheuk AT; Chan L; Czepulkowski B; Berger SA; Yagita H; Okumura K; Farzaneh F; Mufti GJ; Guinn BA
Cancer Immunol Immunother; 2006 Jan; 55(1):68-75. PubMed ID: 15891884
[TBL] [Abstract][Full Text] [Related]
4. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses.
Koya RC; Kasahara N; Pullarkat V; Levine AM; Stripecke R
Leukemia; 2002 Sep; 16(9):1645-54. PubMed ID: 12200676
[TBL] [Abstract][Full Text] [Related]
5. Immunological weapons against acute myeloid leukaemia.
Galea-Lauri J
Immunology; 2002 Sep; 107(1):20-7. PubMed ID: 12225359
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of myeloid leukaemia.
Guinn BA; Mohamedali A; Thomas NS; Mills KI
Cancer Immunol Immunother; 2007 Jul; 56(7):943-57. PubMed ID: 17180671
[TBL] [Abstract][Full Text] [Related]
7. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1.
Hirst WJ; Buggins A; Darling D; Gäken J; Farzaneh F; Mufti GJ
Gene Ther; 1997 Jul; 4(7):691-9. PubMed ID: 9282170
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of acute myeloid leukemia: current approaches.
Smits EL; Berneman ZN; Van Tendeloo VF
Oncologist; 2009 Mar; 14(3):240-52. PubMed ID: 19289488
[TBL] [Abstract][Full Text] [Related]
9. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.
Orleans-Lindsay JK; Deru A; Craig JI; Prentice HG; Lowdell MW
Clin Exp Immunol; 2003 Sep; 133(3):467-75. PubMed ID: 12930376
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
Kaleka G; Schiller G
Leuk Res; 2022 Jan; 112():106732. PubMed ID: 34864447
[TBL] [Abstract][Full Text] [Related]
11. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
Finke J; Nagler A
Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
[TBL] [Abstract][Full Text] [Related]
12. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
[TBL] [Abstract][Full Text] [Related]
13. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
14. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
15. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
Knorr DA; Goldberg AD; Stein EM; Tallman MS
Leuk Lymphoma; 2019 Dec; 60(14):3350-3362. PubMed ID: 31335250
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke J; Buka R; Craddock C
Front Immunol; 2021; 12():659595. PubMed ID: 34012445
[TBL] [Abstract][Full Text] [Related]
19. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
Chan L; Hardwick N; Darling D; Galea-Lauri J; Gäken J; Devereux S; Kemeny M; Mufti G; Farzaneh F
Mol Ther; 2005 Jan; 11(1):120-31. PubMed ID: 15585413
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of AML: future directions.
Lowdell MW; Koh MB
J Clin Pathol; 2000 Jan; 53(1):49-54. PubMed ID: 10767857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
